**ADULT AND PEDIATRIC BLOOD AND MARROW TRANSPLANT PROGRAM**

**DOCUMENT NUMBER:** APBMT-COMM-044

**DOCUMENT TITLE:**
Immune Effector Cell Administration and Patient Management

<table>
<thead>
<tr>
<th>Document Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revision:</strong> 02</td>
</tr>
<tr>
<td><strong>Status:</strong> Release</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Creation Date:</strong> 05 Apr 2021</td>
</tr>
<tr>
<td><strong>Effective Date:</strong> 19 Apr 2021</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Control Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author:</strong> MOORE171</td>
</tr>
<tr>
<td><strong>Previous Number:</strong> APBMT-COMM-044 Rev 01</td>
</tr>
</tbody>
</table>
APBMT-COMM-044
IMMUNE EFFECTOR CELL ADMINISTRATION
AND PATIENT MANAGEMENT

1 PURPOSE

1.1 To outline the care and management of the adult and pediatric patients receiving immune effector cells (IECs), which includes post-infusion monitoring including but not limited to the recognition of cellular therapy complications and emergencies.

1.2 To describe the processes around IEC administration.

2 INTRODUCTION

2.1 Immune Effector Cells (IEC) are cells used to modulate an immune response for therapeutic intent, such as dendritic cells, natural killer cells, T cells, and B cells. This includes, but is not limited to, genetically engineered chimeric antigen receptor T cells (CAR-T cells) and therapeutic vaccines.

2.2 All staff involved in the prescribing, dispensing, or administration of IEC therapy are required to complete training modules, such as Risk Evaluation and Mitigation Strategy (REMS) specific to each individual product.

2.2.1 Components:

2.2.1.1 Training and assessment of knowledge include some or all of the following: prescribing information, medication guides, patient management, and adverse event management.

2.2.1.2 Training for all staff will include the detection of and management of immune effector cellular therapy complications. See related SOP APBMT-COMM-045 Management of Immune Effector Cell Therapy Complications.

2.2.2 Retraining:

2.2.2.1 As training is product specific, retraining for all applicable persons will occur if 12 months lapse without a product being utilized in the institution unless otherwise specified by institutional and/or product manufacturer policy.

2.2.3 Training Documentation and Storage:

2.2.3.1 Most retraining is completed and results stored via online modules through the product manufacturer training website. If such is not available, internal training (i.e. via Duke LMS training site) will occur in compliance with manufacturer recommendations.
2.2.3.2 Knowledge assessment are tracked, and when necessary will be kept on file locally, by staff in the Duke Center for Medication Policy.

2.2.3.3 Current Training Stats are available for review upon request from the Duke Center for Medication Policy.

3 SCOPE AND RESPONSIBILITIES

3.1 Interdisciplinary

3.1.1 The physician, or physician designee, will screen the patient to determine eligibility and place an order for the IEC product and associated supportive care in the electronic medical record (EMR). The physician is ultimately responsible for the care of the patient pre, peri, and post IEC therapy.

3.1.2 The nurse will provide supportive care and administer any treatment ordered by physician.

3.1.3 The pharmacist will ensure immediate access to medications and targeted therapies adequate to manage and/or treat expected complications of IEC administration and in compliance with manufacturer’s requirements, when applicable.

3.1.4 All staff involved in the care of the immune effector cell patient will be responsible for ongoing monitoring of the patient for complications associated with immune effector cell therapy.

3.1.5 In the event that the primary team deems an escalation of care is needed, patients will be promptly transferred to the care of the intensive care service and will include plans for patient monitoring before, during and after transfer and communication of the ongoing care plan.

4 DEFINITIONS/ACRONYMS

4.1 CAR Chimeric Antigen Receptor

4.2 CRS Cytokine Release Syndrome

4.3 EMR Electronic Medical Record

4.4 IECs Immune Effector Cells

4.5 IV Intravenous

4.6 Licensed personnel Physician, Advanced Practice Provider, Nurse

4.7 NS Normal Saline

4.8 REMS Risk Evaluation and Mitigation Strategy

4.9 SOP Standard Operating Procedure

4.10 STCL Stem Cell Transplant Laboratory

5 MATERIALS

5.1 NA
6 EQUIPMENT
6.1 NA

7 SAFETY
7.1 NA

8 PROCEDURE
8.1 Note: For all processes outlined below, first review the manufacturer-specific protocol for IEC therapy, as applicable for the product and patient. Examples include the Clinician Guides for:
8.1.1 Abecma (idecabtagene vicleucel)
8.1.2 Breyanzi (lisocabtagene maraleucel)
8.1.3 Kymriah (tisagenlecleucel)
8.1.4 Tecartus (brexucabtagene autoleucel)
8.1.5 Yescarta (axicabtagene ciloleucel)

8.2 After the patient is determined to be an IEC candidate and prior to therapy initiation, there shall be a consultation, between the patient and a physician who is approved to prescribe IEC therapy, to review the goal and plan of treatment.

8.3 The patient will be screened by a financial care coordinator and social worker for appropriateness and to ensure adequate resources are in place for treatment.

8.4 The patient, parent and/or legally authorized representative, as applicable, will sign applicable consent(s) as per health system policy and product requirements.

8.5 A patient alert card will be provided to all IEC patients or their caregivers along with the following instructions:
8.5.1 The patient or caregiver will carry the patient alert card at all times.
8.5.2 The patient or caregiver will provide the patient alert card to any healthcare provider treating the patient.
8.5.3 The patient will be given instructions related to expectations on remaining within the proximity of the clinical program for follow-up care as medically indicated.
8.5.4 The patient will be reminded of the risks of cytokine release syndrome (CRS), neurologic toxicity, or other potential adverse effects and the need to monitor for these events and to seek immediate medical attention if they occur.
8.5.5 The patient will be instructed to refrain from driving and other hazardous activities following IEC administration when required per manufacturer’s instructions.

8.6 The patient will receive IEC therapy either on the:
8.6.1 Adult Hematology Oncology inpatient unit
8.6.2 Pediatric Transplant and Cellular Therapy inpatient unit
8.6.3 Each program’s corresponding outpatient clinic or infusion room

8.7 The pharmacist and physician will ensure timely availability of appropriate treatment for CRS prior to the initiation of the administration of the IEC product and during the recovery period.

8.8 The physician, advance practice provider (APP), or designee will ensure orders are available in the electronic medical record and include premedication and post intravenous (IV) hydration.

8.9 IEC Administration

8.9.1 Patient will be receive premedication 30-60 minutes before the start of the IEC infusion or as per physician orders.

8.9.2 IEC’s will be delivered in a syringe or infusion bag. Tubing will be primed by nursing staff with normal saline (NS) and directly attached to the patient’s central line.

8.9.3 PRIMING OF THE PRODUCT- ADULT PROGRAM

8.9.3.1 If the IEC product is prepared in a syringe, connect the syringe containing the product directly to port of the IV tubing that is closest to the patient (lowest port).

8.9.3.2 If the IEC product is prepared in an infusion bag, prime a second line with NS and attach to the first IV line at the port closest to the patient (lowest port). Next, remove NS bag used to prime second line from the tubing, ensuring to maintain sterility and attach the tubing to the infusion bag.

8.9.4 PRIMING OF THE PRODUCT- PEDIATRIC PROGRAM

8.9.4.1 If the IEC product is prepared in a syringe, it will be connected to a luer locking stopcock. The male end of the stopcock will be connected directly to the patient. The IEC product will then be administered via direct intravenous push with appropriate intravenous fluids provided at the bedside.

8.10 Note: Do NOT use blood or filtered tubing; Do NOT Irradiate Product.

8.11 The product will be prepared in and released by the Stem Cell Transplant Laboratory (STCL) personnel and transported as outlined by product dispensing guidelines.

8.12 The product will be accepted from the courier by the clinical team and/or nurse. Two licensed personnel will verify the product to be infused by double-checking the paperwork to the product.

8.13 Two licensed personnel will verify the IEC product to the patient’s armband at the bedside and confirm that the patient has received the prescribed pre-medications.

8.14 Vital signs will be monitored and documented at baseline, every 15 minutes until infusion is completed, and 30 minutes post infusion.

8.15 Begin IEC product infusion.
8.15.1 If the patient has a reaction, the physician will be notified, and appropriate medical intervention will be taken. This may include slowing or stopping the infusion.

8.15.2 Reactions may include the following:

- Chills and fever
- Decrease in blood pressure
- Dizziness or light-headedness
- Shortness of breath or difficulty breathing
- Fast heart rate
- Nausea and vomiting
- Muscle and joint aches
- Headache
- Symptoms of Cytokine Release Syndrome
- Symptoms of Macrophage Activation Syndrome
- Symptoms of Tumor Lysis Syndrome

8.15.3 If the patient stabilizes, the product may be resumed at a slower rate after consultation with physician or designee.

8.16 Materials used during the infusion will be discarded in accordance with hospital policy and in accordance with institutional and regulatory requirements. Contact leadership or the STCL manager for product-specific requirements.

8.17 The patient will be observed for a minimum of 1 hour following the infusion providing all vital signs are at baseline and patient is clinically stable. The patient will continue to be monitored for complications, including signs of cytokine release syndrome and neurologic dysfunction for a minimum of the next 2 to 3 weeks and in accordance with manufacturer’s requirements.

8.17.1 In the event of suspected cytokine release syndrome or other complications, refer to APBMT-COMM-045 Management of Immune Effector Cell Therapy Complications for detailed management guidelines.

8.18 Should a deterioration in clinical status occur, there will be rapid escalation of care, increased intensity of monitoring, and relative workup to address complications and will include a written plan for communication of the transfer and ongoing management.

8.19 Communication to clinical staff, intensive care unit, emergency department, and pharmacy shall be comprehensive and timely, as applicable. (See Hospital Policies for Patient Transport).

8.20 Documentation:

8.20.1 Staff will document the infusion on the STCL-SOP-050 Infusion Form and in manufacturer specific databases, as required.

8.20.2 Staff will document the following into the electronic medical record:
8.20.2.1 Vital signs
8.20.2.2 Administration/Infusion times of all medications
8.20.2.3 Administration/Completion times of IEC infusion

8.20.3 Staff will document any adverse experiences on the STCL-GEN-050 Infusion Form and in accordance with regulatory and manufacturer’s requirements, as applicable.

8.21 Once the patient meets criteria for discharge to home, discharge instructions will be reviewed in detail with the patient, caregiver and/or legally authorized representative as applicable.

8.21.1 Discharge instructions will include any expectations for immediate follow-up care along with any restrictions, such as related to driving or other hazardous activity.

8.21.2 At this time, or during subsequent return visits, additional care plans incorporating additional follow-up requirements will be communicated.

8.22 Documents will be maintained per hospital document retention policies.

9 RELATED DOCUMENTS/FORMS

9.1 APBMT-COMM-045 Management of Immune Effector Cell Therapy Complications

9.2 STCL-SOP-050 Infusion Form

9.3 Product-specific Clinician Guides as provided by the manufacturer

10 REFERENCES

10.1 NA
### 11 REVISION HISTORY

<table>
<thead>
<tr>
<th>Revision No.</th>
<th>Author</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>02</td>
<td>J. Frith</td>
<td>- Section 1: Purpose updated to reflect both “care and management” and inclusion of post-infusion monitoring.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 2.2: updated to show training components, retraining requirements, and documentation and storage in alignment (FACT standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 3.1.3: updated to ensure immediate access to medications and targeted therapies adequate to manage and/or treat expected complications of IEC administration and in compliance with manufacturer’s requirements, when applicable. (FACT standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 4: acronyms added for SOP compliance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.1 added to refer users to product specific clinician guides</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.5 added to outline patient alert cards and patient instructions. (FACT Standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.6 updated to reflect current locations for product administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.7: updated to reflect “timely availability”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.10: updated to include “do not irradiate product”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.16 added to reflect requirements for product discard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.17: updated to include “in accordance with the manufacturer's requirements.” (FACT standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.20.3: updated to also include “in accordance with regulatory and manufacturer’s requirements, as applicable.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.21.1 added to specify requirements of discharge instructions (FACT standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.21.2 added to include follow-up requirements (FACT Standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Section 8.22 added to reflect document retention (FACT standard)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Related documents section: updated to include product specific clinician guides</td>
</tr>
</tbody>
</table>
## Signature Manifest

**Document Number:** APBMT-COMM-044  
**Title:** Immune Effector Cell Administration and Patient Management  
**Effective Date:** 19 Apr 2021  

All dates and times are in Eastern Time.

### APBMT-COMM-044 Immune Effector Cell Administration and Patient Management

#### Author

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sally McCollum (MOORE171)</td>
<td></td>
<td>05 Apr 2021, 02:44:44 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Management

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelson Chao (CHA00002)</td>
<td></td>
<td>05 Apr 2021, 02:48:32 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Medical Director

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Kurtzberg (KURTZ001)</td>
<td></td>
<td>05 Apr 2021, 03:23:52 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Quality

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bing Shen (BS76)</td>
<td></td>
<td>05 Apr 2021, 06:40:32 PM</td>
<td>Approved</td>
</tr>
</tbody>
</table>

#### Document Release

<table>
<thead>
<tr>
<th>Name/Signature</th>
<th>Title</th>
<th>Date</th>
<th>Meaning/Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Jordan (BJ42)</td>
<td></td>
<td>06 Apr 2021, 07:50:48 AM</td>
<td>Approved</td>
</tr>
</tbody>
</table>